Motilal Oswal on JSW Steel
The brokerage house has given a ‘Buy’ rating with a target price of Rs 1,350 to JSW Steel. This implyies an upside potential of around 18% from current levels. The brokerage believes that the ongoing restructuring, including the joint venture related to Bhushan Power & Steel (BPSL), could unlock significant value for the company.
Motilal Oswal noted that this restructuring will help JSW Steel “monetize a significant portion of the value created through the turnaround of BPSL” and also strengthen the balance sheet by reducing debt.
The brokerage also pointed out that Japanese steelmaker JFE Steel Corporation already owns around 15% in JSW Steel, and the promoter shareholding is set to increase slightly after the planned changes.The report also highlighted the improving fundamentals, with expectations of double-digit revenue growth in financial years 2026-2027 due to new capacity ramp-up and a recovery in steel prices.
Furthermore, the brokerage house added that the company’s net debt-to-EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) ratio could fall sharply to 1.7 times by FY27.
Motilal Oswal on Aurobindo Pharma
The brokerage has also issued a ‘Buy’ call on Aurobindo Pharma with a target price of Rs 1,430. This suggests an upside potential of around 18%. According to the brokerage report, the company’s diversification strategy across Europe, biosimilars and contract manufacturing is creating new revenue streams. It added that European sales are rising, capacity expansion in China is ongoing, and the company’s biologics business continues to scale through its partnership with Merck Sharp & Dohme (MSD).Motilal Oswal expects steady growth in injectables, new product filings and acquisitions, while the integration of Lannett is also seen as a positive contributor. The report retained the company’s quote that its growth outlook is supported by “accelerated scale-up of the Pen-G/6-APA complex toward full utilization” and an expanding biosimilars pipeline across Europe and the United States.
The brokerage has projected a compounded annual growth rate (CAGR) of 9% in revenue, 14% in EBITDA, and 21% in profit after tax for the financial years 2026 to 2028.
Motilal Oswal on Adani Ports and Special Economic Zone
Motilal Oswal has also maintained a ‘Buy’ rating on Adani Ports and Special Economic Zone (APSEZ) with a target price of Rs 1,770. This translates to a potential upside of around 16%. According to the brokerage report, the company’s cargo profile is becoming more diversified as coal volumes gradually shrink while container and coastal cargo rise.The report highlighted that the logistics arm, Adani Logistics, is expanding rapidly, backed by container trains, inland container depots, warehouses and grain silos. The brokerage reiterated APSEZ’s quote that the company aims to offer “shore-to-door solutions” through an integrated logistics model.
It added that strong cash flows, planned port expansions and overseas acquisitions provide visibility for steady growth in the coming years. Motilal Oswal expects cargo volumes to grow around 8% over financial years 2025 to 2028, supporting a double-digit rise in revenue, EBITDA and profit.# 3 'Buy' Recommendations by Motilal Oswal, with Up to 18% Upside Potential
**By Grok, xAI's Financial Insight Engine | December 4, 2025**
As India's stock market navigates through festive highs and global uncertainties in late 2025, brokerage firms like Motilal Oswal are zeroing in on resilient large-caps with tangible growth catalysts. In a fresh note, Motilal Oswal has slapped 'Buy' ratings on three heavyweights—JSW Steel, Aurobindo Pharma, and Adani Ports—flagging upside potentials of up to 18%. These picks span steel, pharma, and infrastructure, offering a diversified bet on India's industrial revival and export boom.
This isn't scattershot advice; it's rooted in structural tailwinds like debt restructuring, policy incentives, and volume expansions. With the Nifty hovering near 25,000 amid rate-cut hopes, these recommendations could be timely anchors for portfolios eyeing 10-20% returns in the next 12 months. Let's unpack why these stocks are on Motilal Oswal's radar and what the numbers say.
### Why These Metrics Scream 'Opportunity' in 2025
Before the specifics, a quick primer on what makes these calls compelling:
- **'Buy' Rating with Modest Upside**: Targets implying 16-18% gains suggest low-risk entries, ideal for conservative investors. No moonshots here—just steady compounding backed by fundamentals.
- **Sector Tailwinds**: Steel benefits from capex cycles, pharma from PLI schemes, and ports from logistics push. India's FY26 GDP growth forecast of 6.8% (per RBI) amplifies these plays.
- **Valuation Comfort**: Trading at reasonable multiples (e.g., 15x FY28 EV/EBITDA for ports), these aren't frothy bets.
Motilal Oswal's analysis highlights how these firms are leveraging operational efficiencies and strategic moves to outpace peers, potentially delivering double-digit earnings growth through FY28.
### The Three Stocks: Targets, Upsides, and Bull Cases
Here's the breakdown, straight from Motilal Oswal's playbook. Current prices are as of market close on December 3, 2025.
| Stock | Sector | Current Price (Rs) | Target Price (Rs) | Upside Potential | Key Reasons for 'Buy' |
|-------|--------|---------------------|-------------------|------------------|-----------------------|
| JSW Steel | Steel | 1,144 | 1,350 | 18% | Restructuring of Bhushan Power & Steel (BPSL) via JV with JFE Steel to unlock value and slash debt by Rs 35,000 crore; supports deleveraging and capex for 20%+ volume growth. |
| Aurobindo Pharma | Pharmaceuticals | 1,208 | 1,430 | 18% | Scaling Pen-G/6-APA production with Rs 35bn investments under PLI scheme for beta-lactam self-sufficiency; highest US generics sales among peers, plus biosimilars ramp-up for FY26-28 earnings surge. |
| Adani Ports & SEZ | Infrastructure | 1,531 | 1,770 | 16% | 8% cargo volume CAGR through FY28 driving double-digit revenue/EBITDA growth; 28.1% market share, Rs 130bn cash pile, and 1.8x net debt/EBITDA for logistics expansion. |
These aren't isolated calls—Motilal Oswal sees JSW Steel's BPSL pivot as a balance-sheet booster, Aurobindo's API push aligning with 'Make in India', and Adani Ports riding the wave of coastal shipping and privatization.
For JSW Steel, the JV isn't just paperwork; it's set to infuse Rs 24,400 crore by March 2026, freeing up capital for green steel initiatives amid global EV demand. Aurobindo, meanwhile, eyes the $90bn US biosimilars pie by 2034, with its ANDA approvals giving it an edge over rivals. Adani Ports' integrated model—ports plus marine services—positions it for 2-3x industry growth, outpacing the 4-7% sector CAGR.
### Investor Implications in a Choppy Market
With FII outflows pressuring mid-caps, these large-cap 'Buys' offer stability. Similar picks have historically outperformed: Adani Ports is up 45% YTD, while Aurobindo has doubled from 2024 lows. Risks include raw material volatility (steel) and regulatory hurdles (pharma), but Motilal Oswal's 15x EV/EBITDA lens keeps valuations grounded.
In broader context, these align with Motilal Oswal's FY26 optimism: Nifty targets of 28,000, fueled by capex and consumption.
### Actionable Steps for Your Portfolio
1. **Entry Points**: Accumulate on dips—JSW below Rs 1,100, Aurobindo under Rs 1,200, Adani Ports near Rs 1,500.
2. **Monitor Catalysts**: Watch BPSL approvals (JSW), PLI disbursals (Aurobindo), and Q3 cargo data (Adani).
3. **Diversify Smartly**: Allocate 5-10% per stock; pair with defensives like ITC for balance.
Dive into Motilal Oswal's full reports for DCF models and peer comps. As 2025 wraps, these could be your edge in a year of selective rallies.
Thoughts? Spotted other broker gems? Share below. Invest wisely—the market favors the informed.
*Disclaimer: This is not financial advice. Conduct your own due diligence or consult an advisor. Markets carry risks of loss.*
No comments:
Post a Comment